Heart Test Laboratories, Inc. (HSCS)

NASDAQ: HSCS · IEX Real-Time Price · USD
-0.15 (-7.58%)
At close: Jun 28, 2022 4:00 PM
-0.03 (-1.64%)
After-hours: Jun 28, 2022 7:56 PM EDT
Market Cap 14.72M
Revenue (ttm) 25,174
Net Income (ttm) -3.63M
Shares Out 8.04M
EPS (ttm) -0.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 74,110
Open 1.94
Previous Close 1.98
Day's Range 1.81 - 2.08
52-Week Range 1.70 - 3.21
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About HSCS

Heart Test Laboratories is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical usefulness. Our objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences’ first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which ha... [Read more...]

Industry Medical Devices
IPO Date Jun 15, 2022
CEO Andrew Simpson
Employees 13
Stock Exchange NASDAQ
Ticker Symbol HSCS
Full Company Profile

Financial Performance

In 2021, HSCS's revenue was $25,604, a decrease of -60.11% compared to the previous year's $64,182. Losses were -$2.45 million, -35.66% less than in 2020.

Financial Statements


Heart Test Laboratories, Inc. Announces Pricing of $6.375 Million Initial Public Offering and Nasdaq Listing

SOUTHLAKE, Texas, June 15, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI...